Heartflow's FFRCT Cuts Unnecessary Heart Procedures by 44% in Government-Funded Trial
HTFL has more than doubled off its 52-week low of $20.13.
Summary
Independent, government-funded FUSION trial shows Heartflow's FFRCT Analysis reduced unnecessary invasive coronary angiograms by 44% at one year (p<0.001) versus standard CCTA alone. Revascularization rates were identical between groups, confirming the reduction did not compromise necessary interventions. Results were presented as late-breaking science at ESC 2026 and simultaneously published in JACC. This is the first randomized trial to validate FFRCT at the critical post-CCTA decision point, directly supporting guideline-based adoption. The data strengthens Heartflow's clinical moat and could accelerate reimbursement and adoption across its 1,800+ institutional base. Watch for potential updates to appropriate use criteria and payer coverage decisions following this evidence.
At the time of this announcement, HTFL was trading at $48.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $20.13 to $51.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.